Celadon Partners Discloses Majority Stake in Senti Biosciences Following $40M Convertible Note Agreement
SNTI sits 25% above its 52-week low of $0.77 on elevated volume (2.2× avg).
Summary
Celadon Partners will become the majority owner of Senti Biosciences with a 54.6% stake after converting initial convertible notes, signaling potential restructuring or M&A discussions.
Key Events · Ownership and Investor Activity · SNTI
-
Investor Acquires Majority Control
Celadon Partners will beneficially own 54.6% of Senti Biosciences' common stock upon the conversion of the initial $10.0 million tranche of convertible notes, making them the majority shareholder.
-
Potential Restructuring and M&A
Celadon Partners intends to engage in preliminary discussions with the company regarding potential restructuring or merger and acquisition transactions.
-
Highly Dilutive Financing Confirmed
The ownership increase stems from the previously disclosed $40.0 million convertible note agreement, with an initial conversion price of $0.6261 per share, significantly below the current market price.
Analysis · SNTI · Life Sciences
This Schedule 13D/A from Celadon Partners confirms their beneficial ownership will increase to 54.6% of Senti Biosciences' common stock upon the conversion of the initial $10.0 million tranche of convertible notes. This effectively grants Celadon majority control of the company. The filing also indicates Celadon's intent to engage in preliminary discussions regarding potential restructuring or merger and acquisition transactions, signaling a significant strategic shift for Senti Biosciences under new control. This follows the company's 8-K on May 1, 2026, which disclosed the highly dilutive $40.0 million convertible note agreement with Celadon.
How filings like this one have moved
In the 30 days to Oct 22, 2026, 46.1% of the 284 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.53%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SNTI was trading at $0.96 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $29.4M. The 52-week trading range was $0.77 to $3.88. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.